GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CTI BioPharma Corp (LTS:0RLB) » Definitions » EV-to-FCF

CTI BioPharma (LTS:0RLB) EV-to-FCF : -13.83 (As of Jun. 05, 2024)


View and export this data going back to 2008. Start your Free Trial

What is CTI BioPharma EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, CTI BioPharma's Enterprise Value is €1,084.98 Mil. CTI BioPharma's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2023 was €-78.46 Mil. Therefore, CTI BioPharma's EV-to-FCF for today is -13.83.

The historical rank and industry rank for CTI BioPharma's EV-to-FCF or its related term are showing as below:

LTS:0RLB' s EV-to-FCF Range Over the Past 10 Years
Min: -14.44   Med: -2.82   Max: 0.69
Current: -14.44

During the past 13 years, the highest EV-to-FCF of CTI BioPharma was 0.69. The lowest was -14.44. And the median was -2.82.

LTS:0RLB's EV-to-FCF is not ranked
in the Biotechnology industry.
Industry Median: 8.31 vs LTS:0RLB: -14.44

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

As of today (2024-06-05), CTI BioPharma's stock price is €2.78781. CTI BioPharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2023 was €-0.555. Therefore, CTI BioPharma's PE Ratio (TTM) for today is At Loss.


CTI BioPharma EV-to-FCF Historical Data

The historical data trend for CTI BioPharma's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CTI BioPharma EV-to-FCF Chart

CTI BioPharma Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.41 -2.32 -4.70 -2.74 -7.12

CTI BioPharma Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -4.30 -6.30 -7.38 -7.12 -6.61

Competitive Comparison of CTI BioPharma's EV-to-FCF

For the Biotechnology subindustry, CTI BioPharma's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CTI BioPharma's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CTI BioPharma's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where CTI BioPharma's EV-to-FCF falls into.



CTI BioPharma EV-to-FCF Calculation

CTI BioPharma's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=1084.983/-78.456
=-13.83

CTI BioPharma's current Enterprise Value is €1,084.98 Mil.
CTI BioPharma's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €-78.46 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


CTI BioPharma  (LTS:0RLB) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

CTI BioPharma's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=2.78781/-0.555
=At Loss

CTI BioPharma's share price for today is €2.78781.
CTI BioPharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.555.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


CTI BioPharma EV-to-FCF Related Terms

Thank you for viewing the detailed overview of CTI BioPharma's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


CTI BioPharma (LTS:0RLB) Business Description

Traded in Other Exchanges
N/A
Address
3101 Western Avenue, Suite 800, Seattle, WA, USA, 98121
CTI BioPharma Corp is a biopharmaceutical company focused on the acquisition, development, and commercialization of less toxic and more effective cancer therapies. Its therapeutic area is blood-related cancers. Its products under the pipeline include Pacritinib. Pacritinib is an investigational oral kinase inhibitor for the treatment of adult patients with myelofibrosis.

CTI BioPharma (LTS:0RLB) Headlines

No Headlines